Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227784 · ClinicalTrials.gov registry record · Phase 3
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 366
- Enrollment target
NCT02227784 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 366 participants.
The verdict
NCT02227784, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 366 participants
- Enrollment target
Study Summary
The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) and/or diabetes.
Interventions
- DRUG Placebo
- DRUG Ezetimibe
- DRUG Atorvastatin
- DRUG Evacetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02227784
The ClinicalTrials.gov registry entry for NCT02227784 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02227784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02227784 about?
NCT02227784 is a clinical study titled "A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol". The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) and/or diabetes.
What is the current status of trial NCT02227784?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 2014-10. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02227784?
The interventions under investigation include: Placebo (DRUG), Ezetimibe (DRUG), Atorvastatin (DRUG), Evacetrapib (DRUG).
Who is sponsoring clinical trial NCT02227784?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.